Molecular pathways to neurodegeneration

Nature Medicine

Volumn 10, Issue 7, 2004, Pages S2-

  Bossy Wetze, Ella ^a   Schwarzenbacher, Robert ^a   Lipton, Stuart A ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METAL;

ALZHEIMER DISEASE; BRAIN MITOCHONDRION; DENDRITIC CELL; EVIDENCE BASED MEDICINE; FAMILIAL DISEASE; HOMEOSTASIS; HUMAN; MOLECULAR BIOLOGY; MUTATION; NERVE DEGENERATION; NERVE FIBER; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SYNAPSE; SYNAPTIC MEMBRANE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CARRIER PROTEINS; HUMANS; HUNTINGTON DISEASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; ONCOGENE PROTEINS; PARKINSON DISEASE; PEPTIDES; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN KINASES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SERUM AMYLOID A PROTEIN; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 3142596164     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1067     Document Type: Article

References (106)

1. Selkoe, D.J. Folding proteins in fatal ways. Nature 426, 900-904 (2003).
2. Roses, A.D. Alipoprotein E in neurology. Curr. Opin. Neurol. 4, 265-270 (1996).
3. Hardy, J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci. 20, 154-159 (1997).
4. Selkoe, D.J. Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 399, A23-A31 (1999).
5. Delacourte, A. & Buee, L. Tau pathology: A marker of neurodegenerative disorders. Curr. Opin. Neurol. 13, 371-376 (2000).
6. Rossjohn, J. etal. Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat. Struct. Biol. 6, 327-331 (1999).
7. Barnham, K.J. et al. Structure of the Alzheimer’s disease amyloid precursor binding protein. A regulator of neuronal copper homeostasis. J. Biol. Chem. 278, 17401-17407 (2003).
8. Watson, A.A., Fairlie, D.P. & Craik, D.J. Solution structure of methionine-oxidized amyloid p-peptide (1-40). Does oxidation affect conformational switching? Biochemistry37, 12700-12706 (1998).
9. Curtain, C.C. et al. Alzheimer’s disease amyloid-p binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superox- ide dismutase-like subunits. J. Biol. Chem. 276, 20466-20473 (2001).
10. Singleton, A., Myers, A. & Hardy, J. The law of mass action applied to neurode- generative disease: A hypothesis concerning the etiology and pathogenesis of complex diseases. Hum. Mol. Genet. 13 (Spec. no. 1), R123-R126 (2004).
11. Haas, C. & Steiner, H. Alzheimer disease-y-secretase: A complex story of GxGD- type presenilin proteases. Trends Cell Biol. 12, 556-562 (2002).
12. Edbauer, D. et al. Reconstitution of y-secretase activity. Nat. Cell Biol. 5, 486-488 (2003).
13. Haass, C. Take five-BACE and the y-secretase quartet conduct Alzheimer’s amyloid p-peptide generation. EMBO J. 23, 483-488 (2004).
14. Hutton, M., Perez-Tur, J. & Hardy, J. Genetics of Alzheimer’s disease. Essays Biochem. 33, 117-131 (1998).
15. Scheuner, D. et al. Secreted amyloid p-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 2, 864-870 (1996).
16. Borchelt, D.R. et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945 (1997).
17. De Strooper, B. et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390 (1998).
18. Naruse, S. et al. Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron21, 1213-1221 (1998).
19. Lu, D.C. et al. A second cytotoxic proteolytic pepide derived from amyloid p-pro- tein precursor. Nat. Med. 6, 385-386 (2000).
20. Stewart, W.F., Kawas, C., Corrada, M. & Metter, E.J. Risk of Alzheimer’s disease and duration of NSAID use. Neurology48, 626-632 (1997).
21. Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Ap42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
22. Lipton, S.A. Concepts: Turning down but not off-neuroprotection requires a paradigm shift in drug development. Nature 428, 473 (2004).
23. Kamal, A., Stokin, G.B., Yang, Z., Xia, C.H. & Goldstein, L.S. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28, 449-459 (2000).
24. Kamal, A., Almenar-Queralt, A., LeBlanc, J.F., Roberts, E.A. & Goldstein, L.S. Kinesin-mediated axonal transport of a membrane compartment containing p-sec- retase and presenilin-1 requires APP. Nature 414, 643-648 (2001).
25. Pigino, G. et al. Alzheimer’s presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 23, 4499-4508 (2003).
26. Selkoe, D.J. Alzheimer’s disease is a synaptic failure. Science 298, 789-791 (2002).
27. Chapman, P.F. et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2, 271-276 (1999).
28. Walsh, D.M. et al. Naturally secreted oligomers of amyloid p protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
29. Stephan, A., Laroche, S. & Davis, S. Generation of aggregated p-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J. Neurosci. 21, 5703-5714 (2001).
30. Bush, A.I. et al. A novel zinc(II) binding site modulates the function of the pA4 amyloid protein precursor of Alzheimer’s disease. J. Biol. Chem. 268, 16109-16112 (1993).
31. Bush, A.I. et al. Rapid induction of Alzheimer A p amyloid formation by zinc. Science 265, 1464-1467 (1994).
32. Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L. & Markesbery, W.R. Copper, iron and zinc in Alzheimer’s disease senile plaques. J. Neurol. Sci. 158, 47-52 (1998).
33. Dong, J. et al. Metal binding and oxidation of amyloid-p within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42, 2768-2773 (2003).
34. Opazo, C. et al. Metalloenzyme-like activity of Alzheimer’s disease p-amyloid. Cu- dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2. J. Biol. Chem. 277, 40302-40308 (2002).
35. Bush, A.I. Copper, zinc, and the metallobiology of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 17, 147-150 (2003).
36. Huang, X. et al. The A p peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry38, 7609-7616 (1999).
37. Bossy-Wetzel, E. et al. Crosstalk between nitric oxide and zinc pathways to neu- ronal cell death involving mitochondrial dysfunction and p38-activated K+channels. Neuron 41, 351-365 (2004).
38. Bush, A.I. Metal complexing agents as therapies for Alzheimer’s disease. Neurobiol. Aging23, 1031-1038 (2002).
39. Cherny, R.A. et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits p-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30, 665-676 (2001).
40. Ritchie, C.W. et al. Metal-protein attenuation with iodochlorhydroxyquin (clio- quinol) targeting Ap amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch. Neurol. 60, 1685-1691 (2003).
41. Hirai, K. et al. Mitochondrial abnormalities in Alzheimer’s disease. J. Neurosci. 21, 3017-3023 (2001).
42. Anandatheerthavarada, H.K., Biswas, G., Robin, M.A. & Avadhani, N.G. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J. Cell Biol. 161, 41-54 (2003).
43. Casley, C.S. et al. p-Amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol. Dis. 10, 258-267 (2002).
44. Casley, C.S., Canevari, L., Land, J.M., Clark, J.B. & Sharpe, M.A. p-Amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 80, 91-100 (2002).
45. Lustbader, J.W. et al. ABAD directly links Ap to mitochondrial toxicity in Alzheimer’s disease. Science 304, 448-452 (2004).
46. Xu, J. et al. Dopamine-dependent neurotoxicity of a-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600-606 (2002).
47. Hardy, J., Cookson, M.R. & Singleton, A. Genes and parkinsonism. Lancet Neurol. 2, 221-228 (2003).
48. Langston, J.W., Ballard, P., Tetrud, J.W. & Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science219, 979-980 (1983).
49. Langston, J.W. et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Ann. Neurol. 46, 598-605 (1999).
50. Rose, S. et al. Age-related effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyri- dine treatment of common marmosets. Eur. J. Pharmacol. 230, 177-185 (1993).
51. Irwin, I., DeLanney, L.E. & Langston, J.W. MPTP and aging. Studies in the C57BL/6 mouse. Adv. Neurol. 60, 197-206 (1993).
52. Ovadia, A., Zhang, Z. & Gash, D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging 16, 931-937 (1995).
53. Kaur, D. et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson’s disease. Neuron 37, 899-909 (2003).
54. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 3, 1301-1306 (2000).
55. Polymeropoulos, M.H. et al. Mutation in the a-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045-2047 (1997).
56. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
57. Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259 (2003).
58. Valente, E.M. et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304, 1158-1160 (2004)
59. Eriksen, J.L., Dawson, T.M., Dickson, D.W. & Petrucelli, L. Caught in the act. a-Synuclein is the culprit in Parkinson’s disease. Neuron 40, 453-456 (2003).
60. Baptista, M.J., Cookson, M.R. & Miller, D.W. Parkin and a-synuclein: Opponent actions in the pathogenesis of Parkinson’s disease. Neuroscientist 10, 63-72 (2004).
61. Sakata, E. et al. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep. 4, 301-306 (2003).
62. Cookson, M.R. Parkin’s substrates and the pathways leading to neuronal damage. NeuromolecularMed. 3, 1-13 (2003).
63. Cookson, M.R. et al. RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet. 12, 2957-2965 (2003).
64. Imai, Y. et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891-902 (2001).
65. Petrucelli, L. et al. Parkin protects against the toxicity associated with mutant a-synuclein: Proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007-1019 (2002).
66. Staropoli, J.F. et al. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37, 735-749 (2003).
67. Darios, F. et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 12, 517-526 (2003).
68. Yang, Y., Nishimura, I., Imai, Y., Takahashi, R. & Lu, B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37, 911-924 (2003).
69. Tsai, Y.C., Fishman, P.S., Thakor, N.V. & Oyler, G.A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 278, 22044-22055 (2003).
70. Greene, J.C. et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. USA100, 4078-4083 (2003).
71. Palacino, J.J. et al. Mitochondrial dysfunction and oxidative damage in Parkin- deficient mice. J. Biol. Chem. 279, 18614-18622 (2004).
72. Chung, K.K. et al. S-Nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science 304, 1328-1331 (2004)
73. Yao, D., et al. Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosy- lation of parkin regulates its E3 ligase activity. Proc. Natl. Acad. Sci. USA (2004), in press.
74. Cookson, M.R. Pathways to parkinsonism. Neuron 37, 7-10 (2003).
75. Taira, T. et al. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5, 213-218 (2004).
76. Honbou, K. et al. The crystal structure of DJ-1, a protein related to male fertility and Parkinson’s disease. J. Biol. Chem. 278, 31380-31384 (2003).
77. Wilson, M.A., Collins, J.L., Hod, Y., Ringe, D. & Petsko, G.A. The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early-onset Parkinson’s disease. Proc. Natl. Acad. Sci. USA 100, 9256-9261 (2003).
78. Trottier, Y. et al. Polyglutamine expansion as a pathological epitope in Huntington’s disease and four dominant cerebellar ataxias. Nature 378, 403-406 (1995).
79. DiFiglia, M. et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14, 1075-1081 (1995).
80. Panov, A.V. et al. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat. Neurosci. 5, 731-736 (2002).
81. Young, A.B. Huntingtin in health and disease. J. Clin. Invest. 111, 299-302 (2003).
82. Harjes, P. & Wanker, E.E. The hunt for huntingtin function: Interaction partners tell many different stories. Trends Biochem. Sci. 28, 425-433 (2003).
83. Li, H., Gu, X., Dawson, V.L. & Dawson, T.M. Identification of calcium- and nitric oxide-regulated genes by differential analysis of library expression (DAzLE). Proc. Natl. Acad. Sci. USA 101, 647-652 (2004).
84. Andrade, M.A. & Bork, P. HEAT repeats in the Huntington’s disease protein. Nat. Genet. 11, 115-116 (1995).
85. Sittler, A. et al. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol. Cell 2, 427-436 (1998).
86. Sun, Y., Savanenin, A., Reddy, P.H. & Liu, Y.F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276, 24713-24718 (2001).
87. Wanker, E.E. et al. HIP-I: A huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6, 487-495 (1997).
88. Kalchman, M.A. et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat. Genet. 16, 44-53 (1997).
89. Li, X.J. et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature378, 398-402 (1995).
90. Singaraja, R.R. et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum. Mol. Genet. 11, 2815-2828 (2002).
91. Feany, M.B. & La Spada, A.R. Polyglutamines stop traffic: Axonal transport as a common target in neurodegenerative diseases. Neuron 40, 1-2 (2003).
92. Li, H., Li, S.H., Yu, Z.X., Shelbourne, P. & Li, X.J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington’s disease mice. J. Neurosci. 21, 8473-8481 (2001).
93. Gunawardena, S. et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40, 25-40 (2003).
94. Steffan, J.S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature413, 739-743 (2001).
95. Dunah, A.W. et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington’s disease. Science296, 2238-2243 (2002).
96. Obrietan, K. & Hoyt, K.R. CRE-mediated transcription is increased in Huntington’s disease transgenic mice. J. Neurosci. 24, 791-796 (2004).
97. Sugars, K.L., Brown, R., Cook, L.J., Swartz, J. & Rubinsztein, D.C. Decreased cAMP response element-mediated transcription: An early event in exon 1 and full- length cell models of Huntington’s disease that contributes to polyglutamine pathogenesis. J. Biol. Chem. 279, 4988-4999 (2004).
98. Sipione, S. & Cattaneo, E. Modeling Huntington’s disease in cells, flies, and mice. Mol. Neurobiol. 23, 21-51 (2001).
99. Rubinsztein, D.C. Lessons from animal models of Huntington’s disease. Trends Genet. 18, 202-209 (2002).
100. Rosen, D.R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature362, 59-62 (1993).
101. Hough, M.A. et al. Dimer destabilization in superoxide dismutase may result in disease-causing properties: Structures of motor neuron disease mutants. Proc. Natl. Acad. Sci. USA 101, 5976-5981 (2004).
102. Koo, E.H., Lansbury, P.T., Jr. & Kelly, J.W. Amyloid diseases: Abnormal protein aggregation in neurodegeneration. Proc. Natl. Acad. Sci. USA 96, 9989-9990 (1999).
103. Ray, S.S. & Lansbury, P.T., Jr. A possible therapeutic target for Lou Gehrig’s disease. Proc. Natl. Acad. Sci. USA 101, 5701-5702 (2004).
104. Clement, A.M. et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302, 113-117 (2003).
105. Kawahara, Y. et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 427, 801 (2004).
106. Lipton, S.A. Sporadic ALS: Blame it on the editor. Nat. Med. 10, 347 (2004).